TRINETRA › Sectors › Healthcare
Glenmark Pharmaceuticals Limited (GLENMARK) — share price, P/E and fundamentals
Glenmark Pharmaceuticals Limited (NSE: GLENMARK) closed at ₹2,298.70 on 30 Oct 2026, +23.5% over one year, against a 52-week range of ₹1,792.60 – ₹2,537.60.
In the quarter ended 30 Jun 2026 (consolidated, filed 31 Jul 2026) it reported revenue of ₹4,018 cr and net profit of ₹483 cr, a 12.0% net margin; revenue grew 23.1% and profit grew 573.2% year on year.
On four consecutive filed quarters its trailing P/E is 43.4; since 23 May 2025 its own P/E has ranged from 33.7 to 64.1 (median 51.8), and today's reading is higher than 7% of those 355 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 18.4%, ROCE 20.6%, debt-to-equity 0.00, Piotroski F-score 9 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 43% of 63 sector peers; PBT margin higher than 40% of 63 sector peers; ROE higher than 71% of 63 sector peers.
Key figures
| Last close | ₹2,298.70 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -5.4% / -0.0% / +23.5% |
| 52-week low – high | ₹1,792.60 – ₹2,537.60 |
| Market capitalisation | ₹64,869 cr |
| Trailing P/E | 43.4 |
| Price / book | 6.17 |
| EV / EBITDA | 19.0 |
| Earnings yield | 2.3% |
| TTM EPS | ₹53.03 |
| TTM net profit | ₹1,496 cr |
| Quarter revenue | ₹4,018 cr |
| Quarter net profit | ₹483 cr |
| Net margin | 12.0% |
| Revenue growth (YoY) | +23.1% |
| Profit growth (YoY) | +573.2% |
| Return on equity | 18.4% |
| ROCE | 20.6% |
| Debt / equity | 0.00 |
| Current ratio | 1.77 |
| Free cash flow | ₹2,087 cr |
| Piotroski F-score | 9 / 9 |
| Average daily turnover (50 days) | ₹114.1 cr |
Against Healthcare peers
| Metric | GLENMARK | Peer median | Percentile |
|---|---|---|---|
| Net margin | 12.02 | 12.89 | 43 |
| PBT margin | 16.01 | 17.68 | 40 |
| ROE | 18.38 | 13.86 | 71 |
| ROCE | 20.62 | 16.59 | 70 |
| Debt / equity | 0.00 | 0.11 | 12 |
| Cash conversion | 2.53 | 1.25 | 92 |
| Trailing P/E | 43.35 | 43.26 | 51 |
| P/B | 6.17 | 5.88 | 53 |
Questions
What is the P/E ratio of Glenmark Pharmaceuticals Limited?
Glenmark Pharmaceuticals Limited's trailing P/E is 43.4, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 23 May 2025 its P/E has ranged 33.7–64.1.
What were Glenmark Pharmaceuticals Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Glenmark Pharmaceuticals Limited reported revenue of ₹4,018 cr and net profit of ₹483 cr (consolidated), filed with the exchange on 31 Jul 2026.
What is Glenmark Pharmaceuticals Limited's ROE?
Return on equity is 18.4% based on the balance sheet dated 31 Mar 2026.
Does Glenmark Pharmaceuticals Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 31 Mar 2026.
What is GLENMARK's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, GLENMARK traded between ₹1,792.60 and ₹2,537.60.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.